 Drug Monitoring
"Drug Monitoring" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically.
| Descriptor ID |
D016903
|
| MeSH Number(s) |
E01.370.520.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Monitoring".
Below are MeSH descriptors whose meaning is more specific than "Drug Monitoring".
This graph shows the total number of publications written about "Drug Monitoring" by people in this website by year, and whether "Drug Monitoring" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 1 | 1 | | 1994 | 1 | 0 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 3 | 3 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 2 | 3 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 3 | 4 | | 2004 | 0 | 2 | 2 | | 2005 | 2 | 1 | 3 | | 2006 | 2 | 1 | 3 | | 2007 | 2 | 1 | 3 | | 2008 | 0 | 1 | 1 | | 2009 | 1 | 0 | 1 | | 2010 | 4 | 2 | 6 | | 2012 | 1 | 5 | 6 | | 2013 | 2 | 5 | 7 | | 2014 | 0 | 8 | 8 | | 2015 | 1 | 6 | 7 | | 2016 | 2 | 10 | 12 | | 2017 | 3 | 4 | 7 | | 2018 | 2 | 3 | 5 | | 2019 | 3 | 4 | 7 | | 2020 | 2 | 7 | 9 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Monitoring" by people in Profiles.
-
Click B, Barnes EL, Cohen BL, Sands BE, Hanson JS, Rubin DT, Dubinsky MC, Regueiro M, Gazis D, Crawford JM, Long MD. Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD. BMC Gastroenterol. 2022 Feb 19; 22(1):71.
-
Rossman MJ, Gioscia-Ryan RA, Santos-Parker JR, Ziemba BP, Lubieniecki KL, Johnson LC, Poliektov NE, Bispham NZ, Woodward KA, Nagy EE, Bryan NS, Reisz JA, D'Alessandro A, Chonchol M, Sindler AL, Seals DR. Inorganic Nitrite Supplementation Improves Endothelial Function With Aging: Translational Evidence for Suppression of Mitochondria-Derived Oxidative Stress. Hypertension. 2021 04; 77(4):1212-1222.
-
Friedman DM, Kim M, Costedoat-Chalumeau N, Clancy R, Copel J, Phoon CK, Cuneo BF, Cohen R, Masson M, Wainwright BJ, Zahr N, Saxena A, Izmirly PM, Buyon JP. Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. Circ Arrhythm Electrophysiol. 2020 10; 13(10):e008686.
-
White D, MacDonald S, Bull T, Hayman M, de Monteverde-Robb R, Sapsford D, Lavinio A, Varley J, Johnston A, Besser M, Thomas W. Heparin resistance in COVID-19 patients in the intensive care unit. J Thromb Thrombolysis. 2020 Aug; 50(2):287-291.
-
Reinecke I, Solms A, Willmann S, Spiro TE, Peters G, Weitz JI, Mueck W, Garmann D, Schmidt S, Zhang L, Fox KAA, Berkowitz SD. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. J Thromb Thrombolysis. 2020 Jul; 50(1):12-19.
-
Zhang L, Yan X, Fox KAA, Willmann S, Nandy P, Berkowitz SD, Hermanowski-Vosatka A, Weitz JI, Solms A, Schmidt S, Patel M, Peters G. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. J Thromb Thrombolysis. 2020 Jul; 50(1):20-29.
-
Hackshaw MD, Danysh HE, Singh J, Ritchey ME, Ladner A, Taitt C, Camidge DR, Iwata H, Powell CA. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020 Aug; 183(1):23-39.
-
Patil MA, Kompella UB. Noninvasive Monitoring of Choroid-Retina Autofluorescence and Intravitreal Nanoparticle Disposition in Royal College of Surgeon Rats of Different Ages and Retinal Thinning. J Ocul Pharmacol Ther. 2020 Jul/Aug; 36(6):458-466.
-
Schniedewind B, Meyer EJ, Christians U. Long-Term Performance of Laboratory-Developed Liquid Chromatography-Tandem Mass Spectrometry Tests and a Food and Drug Administration-Approved Immunoassay for the Therapeutic Drug Monitoring of Everolimus. Ther Drug Monit. 2020 06; 42(3):421-426.
-
Montesinos P, Roboz GJ, Bulabois CE, Subklewe M, Platzbecker U, Ofran Y, Papayannidis C, Wierzbowska A, Shin HJ, Doronin V, Deneberg S, Yeh SP, Ozcan MA, Knapper S, Cortes J, Pollyea DA, Ossenkoppele G, Giralt S, Döhner H, Heuser M, Xiu L, Singh I, Huang F, Larsen JS, Wei AH. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia. 2021 01; 35(1):62-74.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|